- Home
- PERI vs AUTL Comparison
PERI vs AUTL Comparison
Compare PERI & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PERI | AUTL |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.5M | 368.6M |
| IPO Year | 2006 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PERI | AUTL |
|---|---|---|
| Price | $10.26 | $1.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $14.75 | $8.33 |
| AVG Volume (30 Days) | 401.7K | ★ 3.7M |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $432,361,000.00 | $51,128,000.00 |
| Revenue This Year | N/A | $643.50 |
| Revenue Next Year | $11.12 | $108.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 406.67 |
| 52 Week Low | $7.00 | $1.11 |
| 52 Week High | $11.79 | $3.45 |
Technical Indicators
Market Signals| Indicator | PERI | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 60.74 | 50.59 |
| Support Level | $9.30 | $1.20 |
| Resistance Level | $9.96 | $1.49 |
| Average True Range (ATR) | 0.41 | 0.10 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 54.50 | 64.06 |
Price Performance
Historical ComparisonAbout PERI Perion Network Ltd.
Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.